Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736704 · ClinicalTrials.gov registry record · Phase 1
SNV4818 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Pikavation Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 12
- Study locations
NCT06736704: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Pikavation Therapeutics.
NCT06736704 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Pikavation Therapeutics. The registered enrollment target is 320 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (63% higher). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736704, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Pikavation Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Primary Outcome
-Number of participants experiencing protocol-defined DLTs (Part 1A and 2A only)
Conditions Studied
Interventions
- DRUG SNV4818
- DRUG Fulvestrant
- DRUG Palbociclib
Study Locations (12)
New South Wales
- Chris O'Brien Lifehouse - Camperdown
- Scientia Clinical Research - Randwick
Victoria
- Monash Health - Clayton
- Peter MacCallum Cancer Centre - Melbourne
Ontario
- The Ottawa Hospital Cancer Centre - Ottawa
- University Health Network, Princess Margaret Cancer Centre - Toronto
California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
Pennsylvania
- Thomas Jefferson University-Sidney Kimmel Cancer Center - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06736704 shows while recruiting
NCT06736704 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (63% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which SNV4818 is the first listed.
NCT06736704 lists 12 locations in 9 states (New South Wales, Victoria, Ontario).
Frequently Asked Questions
What is clinical trial NCT06736704 about?
NCT06736704 is a clinical study titled "SNV4818 in Participants With Advanced Solid Tumors". This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
What is the current status of trial NCT06736704?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2025-02-20. Estimated completion is 2027-06.
What conditions does trial NCT06736704 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06736704?
The interventions under investigation include: SNV4818 (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT06736704?
This trial is sponsored by Pikavation Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736704 being conducted?
This trial has 12 study locations across California, Massachusetts, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736704's enrollment target sits among peer trials
320 22nd of 144 higher than 123 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI